Condition: Non-small Cell Lung Cancer · Sponsor: Precision Biotech Taiwan Corp.
Objectives: To determine the safety, tolerability, and efficacy of allogeneic PB103 in patients with IIIb/IV or refractory non-small-cell lung cancer
This description comes directly from the study's public registry record.
Chia Hua Lin, Ph.D. · +886-2-2740-0678 · julielin@precisionthera.com
Always discuss trial participation with your own doctor first.
| Tri-Service General Hospital | Taipei, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04616209